AAM, Biosimilars Council oppose FDA biosimilar naming update

The Association for Accessible Medicines said the Food and Drug Administration's guidance on naming biological products delays the development of biosimilars.

AAM, Biosimilars Council oppose FDA biosimilar naming update
QR Code
Embed the QR code on your website:
Download
Copy